ATE52263T1 - Verbindungen mit entzuendungshemmender aktivitaet, hergestellt durch komplexierung mit beta- cyclodextrin und pharmazeutische zusammensetzungen welche diese enthalten. - Google Patents

Verbindungen mit entzuendungshemmender aktivitaet, hergestellt durch komplexierung mit beta- cyclodextrin und pharmazeutische zusammensetzungen welche diese enthalten.

Info

Publication number
ATE52263T1
ATE52263T1 AT84113923T AT84113923T ATE52263T1 AT E52263 T1 ATE52263 T1 AT E52263T1 AT 84113923 T AT84113923 T AT 84113923T AT 84113923 T AT84113923 T AT 84113923T AT E52263 T1 ATE52263 T1 AT E52263T1
Authority
AT
Austria
Prior art keywords
compounds
complexation
cyclodextrin
beta
pharmaceutical compositions
Prior art date
Application number
AT84113923T
Other languages
German (de)
English (en)
Inventor
Paolo Chiesi
Vittorino Servadio
Original Assignee
Chiesi Farma Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiesi Farma Spa filed Critical Chiesi Farma Spa
Application granted granted Critical
Publication of ATE52263T1 publication Critical patent/ATE52263T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716Glucans
    • A61K31/724Cyclodextrins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08BPOLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C08B37/0015Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nanotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medical Informatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
AT84113923T 1984-02-22 1984-11-17 Verbindungen mit entzuendungshemmender aktivitaet, hergestellt durch komplexierung mit beta- cyclodextrin und pharmazeutische zusammensetzungen welche diese enthalten. ATE52263T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT19735/84A IT1196033B (it) 1984-02-22 1984-02-22 Composto ad attivita' antiinfiammatoria ottenuto per complessazione con beta-ciclodestrina e relative formulazioni farmaceutiche
EP84113923A EP0153998B1 (en) 1984-02-22 1984-11-17 New compounds having antiinflammatory activity, obtained by complexation with beta-cyclodextrin, and pharmaceutical compositions containing them

Publications (1)

Publication Number Publication Date
ATE52263T1 true ATE52263T1 (de) 1990-05-15

Family

ID=11160778

Family Applications (1)

Application Number Title Priority Date Filing Date
AT84113923T ATE52263T1 (de) 1984-02-22 1984-11-17 Verbindungen mit entzuendungshemmender aktivitaet, hergestellt durch komplexierung mit beta- cyclodextrin und pharmazeutische zusammensetzungen welche diese enthalten.

Country Status (19)

Country Link
US (1) US4603123A (enExample)
EP (1) EP0153998B1 (enExample)
JP (1) JPS60208979A (enExample)
KR (1) KR870001960B1 (enExample)
AT (1) ATE52263T1 (enExample)
AU (1) AU550007B2 (enExample)
BE (1) BE900836A (enExample)
CA (1) CA1234106A (enExample)
DE (2) DE3482041D1 (enExample)
DK (1) DK164911C (enExample)
ES (1) ES536909A0 (enExample)
IE (1) IE58231B1 (enExample)
IT (1) IT1196033B (enExample)
MY (1) MY101374A (enExample)
NZ (1) NZ211114A (enExample)
PH (1) PH22075A (enExample)
PT (1) PT79997B (enExample)
SG (1) SG53690G (enExample)
ZA (1) ZA848156B (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU43290B (en) * 1986-11-13 1989-06-30 Lek Tovarna Farmacevtskih Process for preparing inclusioned complex of ibuproxane with beta-cyclodextrine
IT1204725B (it) * 1987-06-17 1989-03-10 Edmond Pharma Srl Complessi di inclusione del dipiridamolo con ciclodestrine
NZ225045A (en) * 1987-07-01 1990-06-26 Janssen Pharmaceutica Nv Antiviral pharmaceutical compositions containing cyclodextrin and an antiviral agent
US5002935A (en) * 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
US5017566A (en) * 1987-12-30 1991-05-21 University Of Florida Redox systems for brain-targeted drug delivery
DE3809808A1 (de) * 1988-03-23 1989-10-05 Hexal Pharma Gmbh & Co Kg Feste, insbesondere festorale und rektale, etofenamat enthaltende arzneimittel
US5997856A (en) * 1988-10-05 1999-12-07 Chiron Corporation Method and compositions for solubilization and stabilization of polypeptides, especially proteins
IT1241088B (it) * 1990-03-27 1993-12-29 Chiesi Farma Spa Procedimento per la preparazione di complessi piroxicam/ciclodestrina,prodotti ottenuti e loro composizioni farmaceutiche
US5180716A (en) * 1990-08-01 1993-01-19 The Regents Of The University Of California Cyclodextrin complexes for neuraxial administration of drugs
EP0519428B1 (en) * 1991-06-21 2000-09-20 Takeda Chemical Industries, Ltd. Cyclodextrin compositions with fumagillol derivates
US20040014695A1 (en) * 1992-06-19 2004-01-22 Supergen, Inc. Pharmaceutical formulation
US5602112A (en) 1992-06-19 1997-02-11 Supergen, Inc. Pharmaceutical formulation
IL111184A (en) * 1993-10-08 2000-08-13 Farmarc Nederland B V Of Cito Crystalline inclusion complex of diclofenac with unsubstituted beta-cyclodextrin
US5646131A (en) * 1994-02-22 1997-07-08 The Arab Company For Drug Industries And Medical Applicances (Acdima) Method for solubilizing drugs using cyclodextrins and carboxylic acids
IT1269578B (it) * 1994-04-22 1997-04-08 Chiesi Farma Spa Complessi di inclusione multicomponente ad elevata solubilita' costituiti da un farmaco di tipo acido, una ciclodestrina e una base.
ZA959469B (en) * 1994-11-15 1996-05-15 South African Druggists Ltd Pharmaceutical composition
US5824668A (en) * 1996-11-07 1998-10-20 Supergen, Inc. Formulation for administration of steroid compounds
UA57734C2 (uk) 1996-05-07 2003-07-15 Пфайзер Інк. Комплекси включення арилгетероциклічних солей
US6667056B2 (en) * 1997-07-23 2003-12-23 Chiesi Farmaceutici S.P.A. Pharmaceutical compositions containing an effervescent acid-base couple
IT1293764B1 (it) * 1997-07-23 1999-03-10 Chiesi Farma Spa Composizioni farmaceutiche sotto forma di compresse effervescenti contenenti un principio attivo instabile in presenza di acqua
FR2786395A1 (fr) * 1998-12-01 2000-06-02 Virbac Sa Compositions seches solubles en presence d'eau et evitant la reaction de maillard a l'etat sec, leur preparation et leurs applications
TWI242015B (en) 1999-11-29 2005-10-21 Akzo Nobel Nv 6-mercapto-cyclodextrin derivatives: reversal agents for drug-induced neuromuscular block
AU2002241611A1 (en) * 2000-12-04 2002-06-18 Sepracor, Inc. Orally-bioavailable formulations of fentanyl and congeners thereof
GB0205253D0 (en) * 2002-03-06 2002-04-17 Univ Gent Immediate release pharmaceutical granule compositions and a continuous process for making them
DE60219609T2 (de) * 2002-06-17 2008-01-03 Chiesi Farmaceutici S.P.A. Prozess für die Vorbereitung von Piroxicam: Beta-Cyclodextrin Einschlusskomplexe
EP1582221A1 (en) * 2004-03-31 2005-10-05 Chiesi S.A. Pharmaceutical oral compositions with a taste masking effect
JP5091661B2 (ja) 2004-04-01 2012-12-05 ピエール ファーブル メディカモン 超臨界co2と錯体相互作用剤を用いる方法によって得られる包接錯体
DE502004002443D1 (de) * 2004-04-15 2007-02-08 Helm Ag Verfahren zur Herstellung von freifliessenden, pulverförmigen Valsartan-Adsorbaten
US20060024922A1 (en) * 2004-07-27 2006-02-02 Da-Tung Wen Method for cutting wafer
AU2005268972A1 (en) * 2004-08-02 2006-02-09 Chiesi Farmaceutici S.P.A. A process for the preparation of a piroxicam: beta­cyclodextrin inclusion compound
FR2876910B1 (fr) 2004-10-21 2007-04-13 Pierre Fabre Medicament Sa Complexe comprenant la mequitazine, une cyclodextrine et un agent d'interaction
US20070009532A1 (en) * 2005-07-06 2007-01-11 Branimir Sikic Treatment of patients with cancer using a calicheamicin-antibody conjugate in combination with zosuquidar
US20070010487A1 (en) * 2005-07-06 2007-01-11 Jeff Schwegman Chemotherapeutic formulations of zosuquidar trihydrochloride and modified cyclodextrins
US20070010465A1 (en) * 2005-07-06 2007-01-11 Branimir Sikic Zosuquidar, daunorubicin, and cytarabine for the treatment of cancer
US20070010486A1 (en) * 2005-07-06 2007-01-11 Jeff Schwegman Chemotherapeutic formulations of zosuquidar trihydrochloride and modified cyclodextrins
US20070010485A1 (en) * 2005-07-06 2007-01-11 Jeff Schwegman Chemotherapeutic formulations of zosuquidar trihydrochloride and modified cyclodextrins
GB0612695D0 (en) * 2006-06-27 2006-08-09 Univ Gent Process for preparing a solid dosage form
CL2007003876A1 (es) * 2007-12-28 2008-03-07 Univ De Concepcion Y Lab Andro Complejo de inclusion que esta formado por disulfiram y ciclodextrina; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento de la dependencia de alcohol y cocaina.
KR101383941B1 (ko) * 2012-03-09 2014-04-10 동아에스티 주식회사 피록시캄 또는 약제학적으로 허용되는 그의 염과 히알루론산 또는 약제학적으로 허용되는 그의 염의 안정한 액상 조성물 및 그 제조방법

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2827452A (en) * 1955-05-31 1958-03-18 Univ Minnesota Stabilization of materials
US3969338A (en) * 1971-03-15 1976-07-13 Institut National De La Recherche Agronomique Protein obtained from cakes of vegetable origin
HU184066B (en) * 1979-12-28 1984-06-28 Chinoin Gyogyszer Es Vegyeszet Plant growth regulating substance and process for preparing such compound
HU182217B (en) * 1980-10-17 1983-12-28 Chinoin Gyogyszer Es Vegyeszet Process for producing inclusive complexes of cyclodextrines and strong inorganic oxyacids
JPS5838250A (ja) * 1981-09-01 1983-03-05 Teikoku Chem Ind Corp Ltd 複合体
JPS58126810A (ja) * 1981-12-24 1983-07-28 Kaken Pharmaceut Co Ltd 抗炎症眼科用液剤およびその製法
JPS5920230A (ja) * 1982-07-19 1984-02-01 チバ−ガイギ−・アクチエンゲゼルシヤフト ピルプロフエン含有薬剤

Also Published As

Publication number Publication date
DK76085A (da) 1985-08-23
DK164911B (da) 1992-09-07
US4603123A (en) 1986-07-29
ES8504789A1 (es) 1985-05-01
JPS60208979A (ja) 1985-10-21
DK164911C (da) 1993-01-18
IE850325L (en) 1985-08-22
BE900836A (fr) 1985-02-15
PH22075A (en) 1988-05-20
ES536909A0 (es) 1985-05-01
JPH0370705B2 (enExample) 1991-11-08
IT1196033B (it) 1988-11-10
DE153998T1 (de) 1986-04-10
DE3482041D1 (de) 1990-05-31
EP0153998A3 (en) 1987-01-14
NZ211114A (en) 1987-09-30
SG53690G (en) 1990-11-23
EP0153998B1 (en) 1990-04-25
AU550007B2 (en) 1986-02-27
ZA848156B (en) 1985-06-26
PT79997A (en) 1985-03-01
IT8419735A0 (it) 1984-02-22
KR870001960B1 (ko) 1987-10-23
KR850006133A (ko) 1985-10-02
AU3892385A (en) 1985-08-29
CA1234106A (en) 1988-03-15
MY101374A (en) 1991-10-23
EP0153998A2 (en) 1985-09-11
PT79997B (en) 1987-01-13
DK76085D0 (da) 1985-02-19
IE58231B1 (en) 1993-08-11

Similar Documents

Publication Publication Date Title
ATE52263T1 (de) Verbindungen mit entzuendungshemmender aktivitaet, hergestellt durch komplexierung mit beta- cyclodextrin und pharmazeutische zusammensetzungen welche diese enthalten.
DE3688114D1 (de) Inklusionskomplexe von 7-isopropoxy-isoflavon mit cyclodextrinen, verfahren zu deren herstellung und diese inklusionskomplexe enthaltende pharmazeutische praeparate.
EP0300526A3 (en) Antiviral pharmaceutical compositions containing cyclodextrins
AU591245B2 (en) A deodorant composition and use thereof
FI904230A0 (fi) Akrylsyraderivat.
GEP19960468B (en) Method of producing derivatives of isoquinoline
ATE95070T1 (de) Pharmazeutische zusammensetzung mit gehalt an einer mischung von kollagen und einem antiseptischen und/oder entzuendungshemmenden wirkstoff und verfahren zu ihrer herstellung.
ATE13297T1 (de) Piperidyliden-derivate, deren herstellung und diese enthaltende pharmazeutische zusammensetzungen.
DE69129693D1 (de) Verwendung von nickel und bromide ionen für die behandlung von psoriasis
DK0559612T3 (da) Dioxolanderivater som pesticider
ATE43598T1 (de) Verbindungen mit aktivitaet gegen aggregation von blutplaettchen, verfahren zu ihrer herstellung und diese verbindungen enthaltende pharmazeutische zusammensetzungen.
RU93016862A (ru) Водно-глицериновый комплекс (2,3-диоксипропил)-орто-титана-хлорид
JPS56147704A (en) Dermatological composition
FR2652086B1 (fr) Compose nouveau d'origine vegetale, derive de l'acide cafeique, l'oraposide; composition a usage therapeutique et composition dermato-cosmetique le contenant.
MX9703839A (es) Soluciones intravenosas de lubeluzol.
KR940014266A (ko) 제오라이트를 이용한 분뇨 처리방법
KR890007717A (ko) 약제 디스펜서
Strichartz The binding of saxitoxin to nerve tissue and its antagonism by various agen.
Fernelius Breakthroughs and quantum jumps
ES8303451A1 (es) "procedimiento para la preparacion de d-homo-4,17-androstadien-3-ona".
KR850007241A (ko) 인분을 주재로 한 고단위 비료 제법
IT1173763B (it) Derivati dell'acido 3-mercapto-2-oxo-1-pirrolidinacetico,procedimento di preparazione e composizioni farmaceutiche che li contengono
DE59009647D1 (de) Stabilisiertes Reagenzgemisch.
GT198800003A (es) Derivados de tetrahidronaftaleno e indano.
BR9609937A (pt) Composição contendo ácido mefenâmico em associação com codeìna

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time